Altimmune (ALT) Total Liabilities (2010 - 2026)

Altimmune (ALT) has 17 years of Total Liabilities data on file, last reported at $51.6 million in Q1 2026.

• Total Liabilities for Q1 2026 came in at $51.6 million, up 241.98% year-over-year; the trailing twelve-month figure through Mar 2026 was $51.6 million (up 241.98% YoY), and the FY2025 annual result was $55.0 million, up 248.38% from the prior year.
• Total Liabilities fell to $51.6 million in Q1 2026 per ALT's latest filing, from $55.0 million in the prior quarter.
• Over five years, Total Liabilities peaked at $55.0 million in Q4 2025 and troughed at $14.5 million in Q3 2024.
• A 5-year average of $23.3 million and a median of $19.4 million in 2023 frame the typical range for Total Liabilities.
• The sharpest annual moves came in 2022 and 2025: Total Liabilities declined 26.75% in 2022, then soared 248.38% in 2025.
• A 5-year view of Total Liabilities shows it stood at $21.6 million in 2022, then dropped by 23.55% to $16.5 million in 2023, then fell by 4.49% to $15.8 million in 2024, then soared by 248.38% to $55.0 million in 2025, then retreated by 6.17% to $51.6 million in 2026.
• Business Quant data shows ALT's Total Liabilities at $51.6 million in Q1 2026, $55.0 million in Q4 2025, and $32.8 million in Q3 2025.